

01 June 2024

India | Equity Research | Q4FY24 results review

Tarsons Products

Pharma

Nerbe acquisition weighs on performance

The acquisition of Nerbe's (Germany) low-margin business and a slowing in the life sciences industry impacted Tarsons Products' (Tarsons) Q4FY24 performance; its numbers fell short of our expectations too. Tarson's standalone business fared better – exports grew faster, at ~12% YoY in Q4FY24, and domestic sales were up ~2% YoY. Panchla plant is expected to commence operations in Q2FY25 while the cell culture unit will be operational in Q4FY25. The Panchla plant can generate revenues of INR 4bn at peak capacity in three–five years post commercialisation. We cut FY25E/26E EPS by 20%/29%, factoring in lower sales and margins of Nerbe (CY23 revenue/EBITDA of EUR 8mn/EUR 0.2mn). We lower our rating to ADD (Buy earlier). TP revised to INR 445 at 17x FY26E EV/EBITDA (from INR 625 at 17x FY26E EV/EBITDA).

Revenue growth picking up, margins though muted

Tarsons' Q4FY24 revenue grew 28.8% YoY (down 71.1% QoQ) to INR 1.1bn (I-Sec: INR 966mn) supported by exports and the acquisition of Nerbe. Gross margin contracted 660bps YoY (-450bps QoQ) to 68.6%, marred by change in product mix. EBITDA declined 13.5% YoY (+48.3% QoQ) to INR 339mn (I-Sec: INR 394mn), margin contracted 1570bps (-490bps QoQ) to 32.1%. Adj. PAT declined 45% YoY (+26.5% QoQ) to INR 126mn (I-Sec: INR 195mn).

Standalone business' sales growth reviving

Tarson's domestic business accounted for 59% of its Q4FY24 standalone revenue, growing 1.7% YoY/28.3% QoQ to INR 590mn driven by a revival in demand from key customers. Share of exports rose to 44% of sales, as against 29% in Q4FY23 and 26% in Q3FY23. Export revenue grew 12%/86.7% QoQ to INR 280mn. Leveraging Nerbe's distribution strength and manufacturing capabilities in India, Tarson aims to improve its export footprint to ~120 countries (45 currently) in the next five–ten years.

Capacity expansion on track

Tarsons is incurring capex of INR 6bn (INR 4.5bn spent so far) for two new plants at Panchla and Amta. The Panchla plant will be commercialised in Q2FY25 and may reach optimum capacity utilisation in the next four–five years; it can potentially generate revenue of ~INR 4bn at peak utilisation. The Amata plant may not add incremental revenues to the company.

Financial Summary

Y/E March (INR mn)	FY23A	FY24A	FY25E	FY26E
Net Revenue	2,832	2,964	3,933	4,439
EBITDA	1,298	998	1,338	1,522
EBITDA Margin (%)	45.8	33.7	34.0	34.3
Net Profit	807	426	663	741
EPS (INR)	15.2	8.0	12.5	13.9
EPS % Chg YoY	(19.8)	(47.2)	55.4	11.8
P/E (x)	27.3	51.7	33.3	29.8
EV/EBITDA (x)	17.3	24.4	18.2	15.8
RoCE (%)	13.8	6.2	7.9	8.3
RoE (%)	15.2	7.2	10.3	10.3

Abdulkader Puranwala

abdulkader.puranwala@icicisecurities.com
+91 22 6807 7339

Market Data

Market Cap (INR)	22bn
Market Cap (USD)	264mn
Bloomberg Code	TARSONS IN
Reuters Code	TARO BO
52-week Range (INR)	646 /390
Free Float (%)	29.0
ADTV-3M (mn) (USD)	0.4

Price Performance (%)	3m	6m	12m
Absolute	(11.4)	(8.7)	(25.9)
Relative to Sensex	(13.4)	(19.1)	(44.0)

Earnings Revisions (%)	FY25E	FY26E
Revenue	(12.7)	(14.8)
EBITDA	(20.2)	(23.3)
EPS	(20.2)	(29.3)

Previous Reports

17-02-2024: [Q3FY24 results review](#)23-12-2023: [Company Update](#)

Valuation

Tarson's base business is showing signs of revival with the company registering growth across India and its export geographies in a seasonally strong quarter. Outlook for its base business is improving, as per management, and the business is expected to book EBITDA margins of 40%, as growth picks up in this portfolio. Tarsons had acquired Germany-based Nerbe (EUR 8mn revenue in CY24) in Dec'23; Q4FY24 was the first full-quarter of acquiring this business. Management envisages peak margins in the business to be between ~14–15%, as it plans to shift manufacturing of over 2,000 of Nerbe's SKUs to Tarson's India-based plants. Consolidation of Nerbe and commercialisation of the two new plants are expected to keep margins in check.


We reduce our FY25E/FY26E EPS by 20%/29% to factor in lower sales and margins of Nerbe. We expect revenue to grow at 22.4% CAGR with EBITDA/PAT CAGRs of 23.5%/31.8% over FY24–26E. Margins may improve a mere 60bps to 34.3% in FY26E due to overheads pertaining to commissioning of new plants. We expect RoE/RoCE of 10.3%/8.3% in FY26E. The stock has corrected ~24% post the announcement of the acquisition of Nerbe, factoring in its impact on near term performance of the company. The stock currently trades at valuations of 33.3x FY25E and 29.8x FY26E earnings and EV/EBITDA multiple of 18.4x FY25E and 15.9x FY26E. We lower our rating to **ADD** (from **Buy**) with a lower target price of INR 445 at 17x FY26E EV/EBITDA (earlier TP INR 625, based on 17x FY26E EV/EBITDA).

Key downside risks: Intensified competition; and disruption in distribution network.


Exhibit 1: Quarterly review

INR mn	Q4FY24	Q4FY23	YoY %	Q3FY24	QoQ %	FY24	FY23	YoY %
Net Sales	1,057	821	28.8	618	71.1	2,964	2,832	4.6
Gross Profit	725	617	17.5	451	60.7	2,142	2,182	(1.8)
Gross margins (%)	68.6	75.2	-660bps	73.0	-450bps	72.3	77.0	-480bps
EBITDA	339	393	(13.5)	229	48.3	998	1,298	(23.1)
EBITDA margins (%)	32.1	47.8	-1570bps	37.0	-490bps	33.7	45.8	-1210bps
Other income	34	22	55.5	32	4.3	115	119	(3.8)
PBIT	373	414	(9.9)	261	42.9	1,113	1,417	(21.5)
Depreciation	123	83	49.0	101	22.5	404	285	41.7
Interest	43	21	105.7	25	69.2	101	45	126.5
PBT	207	311	(33.3)	136	53.1	608	1,087	(44.1)
Tax	67	83	(18.6)	36	85.7	181	280	(35.3)
Minority Interest	-	-	-	-	-	-	-	-
Reported PAT	140	228	(38.6)	99	41.2	426	807	(47.2)
Adjusted PAT	126	228	(45.0)	99	26.5	426	807	(47.2)


Source: I-Sec research, Company data

Exhibit 2: Stable outlook for domestic market



Source: Company data, I-Sec research

Exhibit 3: New launches and capacities may prop growth in domestic business



Source: Company data, I-Sec research

Exhibit 4: Exports revert to growth track



Source: Company data, I-Sec research

Exhibit 5: Export growth may be driven by foray in new geographies



Source: Company data, I-Sec research

Exhibit 6: Healthy growth in base and Nerbe consolidation boosts growth



Source: Company data, I-Sec research

Exhibit 7: Revenue to grow at 22.4% CAGR over FY24-26E



Source: Company data, I-Sec research

Exhibit 8: Margins contracted due to increasing cost and Nerbe



Source: Company data, I-Sec research

Exhibit 9: Commercialisation of new plants may keep margins in check in the near term


Source: Company data, I-Sec research

Exhibit 10: Adj. PAT declined 45% YoY


Source: Company data, I-Sec research

Exhibit 11: Profit growth is likely to pick up in FY25E


Source: Company data, I-Sec research

Exhibit 12: Shareholding pattern

%	Sep'23	Dec'23	Mar'24
Promoters	47.3	47.3	47.3
Institutional investors	11.1	9.4	8.3
MFs and other	2.5	2.2	0.0
FIs/ Banks	-	-	-
Insurance Cos.	0.7	0.0	0.0
FII	7.9	7.2	8.3
Others	41.6	43.3	44.4

Source: Bloomberg, I-Sec research

Exhibit 13: Price chart


Source: Bloomberg, I-Sec research

Financial Summary

Exhibit 14: Profit & Loss

(INR mn, year ending March)

	FY23A	FY24A	FY25E	FY26E
Net Sales	2,832	2,964	3,933	4,439
Operating Expenses	884	1,144	1,455	1,630
EBITDA	1,298	998	1,338	1,522
EBITDA Margin (%)	45.8	33.7	34.0	34.3
Depreciation & Amortization	285	404	497	610
EBIT	1,013	594	841	912
Interest expenditure	45	101	108	95
Other Non-operating Income	119	115	152	172
Recurring PBT	1,087	608	885	990
Profit / (Loss) from Associates	-	-	-	-
Less: Taxes	(280)	(181)	(223)	(249)
PAT	807	426	663	741
Less: Minority Interest	-	-	-	-
Extraordinaries (Net)	-	-	-	-
Net Income (Reported)	807	426	663	741
Net Income (Adjusted)	807	426	663	741

Source Company data, I-Sec research

Exhibit 15: Balance sheet

(INR mn, year ending March)

	FY23A	FY24A	FY25E	FY26E
Total Current Assets	2,520	2,353	1,522	1,787
of which cash & cash eqv.	600	226	(111)	(55)
Total Current Liabilities & Provisions	330	559	515	528
Net Current Assets	2,191	1,794	1,007	1,260
Investments	41	47	50	52
Net Fixed Assets	2,177	2,478	5,232	5,222
ROU Assets	66	188	188	188
Capital Work-in-Progress	1,190	2,670	670	670
Total Intangible Assets	5	691	691	691
Other assets	1,236	1,252	1,661	1,875
Deferred Tax assets	22	42	42	42
Total Assets	6,927	9,163	9,541	10,000
Liabilities				
Borrowings	1,106	2,568	2,268	1,968
Deferred Tax Liability	54	92	92	92
provisions	-	2	-	-
other Liabilities	73	250	263	276
Equity Share Capital	5,693	6,129	6,791	7,532
Reserves & Surplus	-	-	-	-
Total Net Worth	5,693	6,129	6,791	7,532
Minority Interest	-	-	-	-
Total Liabilities	6,927	9,163	9,541	10,000

Source Company data, I-Sec research

Exhibit 16: Cashflow statement

(INR mn, year ending March)

	FY23A	FY24A	FY25E	FY26E
Operating Cashflow	756	1,027	1,318	1,048
Working Capital Changes	(349)	86	470	(187)
Capital Commitments	(1,889)	(1,840)	(1,252)	(602)
Free Cashflow	2,645	2,867	2,571	1,650
Other investing cashflow	104	(1,010)	-	-
Cashflow from Investing Activities	(1,785)	(2,850)	(1,252)	(602)
Issue of Share Capital	-	-	-	-
Interest Cost	(45)	(101)	(108)	(95)
Inc (Dec) in Borrowings	-	-	-	-
Dividend paid	-	-	-	-
Others	816	438	(295)	(295)
Cash flow from Financing Activities	771	337	(403)	(389)
Chg. in Cash & Bank balance	(259)	(1,486)	(337)	56
Closing cash & balance	600	(886)	(111)	(55)

Source Company data, I-Sec research

Exhibit 17: Key ratios

(Year ending March)

	FY23A	FY24A	FY25E	FY26E
Per Share Data (INR)				
Reported EPS	15.2	8.0	12.5	13.9
Adjusted EPS (Diluted)	15.2	8.0	12.5	13.9
Cash EPS	20.5	15.6	21.8	25.4
Dividend per share (DPS)	-	-	-	-
Book Value per share (BV)	107.0	115.2	127.6	141.6
Dividend Payout (%)	-	-	-	-
Growth (%)				
Net Sales	(5.8)	4.6	32.7	12.9
EBITDA	(15.0)	(23.1)	34.0	13.8
EPS (INR)	(19.8)	(47.2)	55.4	11.8
Valuation Ratios (x)				
P/E	27.3	51.7	33.3	29.8
P/CEPS	20.2	26.5	19.0	16.3
P/BV	3.9	3.6	3.2	2.9
EV / EBITDA	17.3	24.4	18.2	15.8
P / Sales	7.8	7.4	5.6	5.0
Dividend Yield (%)	-	-	-	-
Operating Ratios				
Gross Profit Margins (%)	77.0	72.3	71.0	71.0
EBITDA Margins (%)	45.8	33.7	34.0	34.3
Effective Tax Rate (%)	25.8	29.8	25.2	25.2
Net Profit Margins (%)	28.5	14.4	16.8	16.7
NWC / Total Assets (%)	31.8	22.1	13.3	15.0
Net Debt / Equity (x)	0.1	0.4	0.3	0.3
Net Debt / EBITDA (x)	0.4	2.3	1.7	1.3
Profitability Ratios				
RoCE (%)	13.8	6.2	7.9	8.3
RoE (%)	15.2	7.2	10.3	10.3
RoIC (%)	15.7	6.5	8.0	8.2
Fixed Asset Turnover (x)	0.5	0.4	0.4	0.4
Inventory Turnover Days	143	162	87	81
Receivables Days	82	98	78	72
Payables Days	12	18	11	10

Source Company data, I-Sec research

This report may be distributed in Singapore by ICICI Securities, Inc. (Singapore branch). Any recipients of this report in Singapore should contact ICICI Securities, Inc. (Singapore branch) in respect of any matters arising from, or in connection with, this report. The contact details of ICICI Securities, Inc. (Singapore branch) are as follows: Address: 10 Collyer Quay, #40-92 Ocean Financial Tower, Singapore - 049315, Tel: +65 6232 2451 and email: navneet_babbar@icicisecuritiesinc.com, Rishi_agrawal@icicisecuritiesinc.com.

"In case of eligible investors based in Japan, charges for brokerage services on execution of transactions do not in substance constitute charge for research reports and no charges are levied for providing research reports to such investors."

New I-Sec investment ratings (all ratings based on absolute return; All ratings and target price refers to 12-month performance horizon, unless mentioned otherwise)
BUY: >15% return; ADD: 5% to 15% return; HOLD: Negative 5% to Positive 5% return; REDUCE: Negative 5% to Negative 15% return; SELL: < negative 15% return

ANALYST CERTIFICATION

I/We, Abdulkader Puranwala, MBA; authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of the ICICI Securities Inc. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, *inter alia*, engaged in the business of stock brokering and distribution of financial products. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager, Research Analyst and Alternative Investment Fund. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities AIF Trust's SEBI Registration number is IN/AIF3/23-24/1292. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Institutional Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Retail Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances. This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/ beneficial ownership of one percent or more or other material conflict of interest in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

This report has not been prepared by ICICI Securities, Inc. However, ICICI Securities, Inc. has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk free return to the investors.

Name of the Compliance officer (Research Analyst): Mr. Atul Agrawal, Contact number: 022-40701000, **E-mail Address** : complianceofficer@icicisecurities.com

For any queries or grievances: [Mr. Prabodh Avadhoot](mailto:Mr.Prabodh.Avadhoot) Email address: headservicequality@icicidirect.com Contact Number: 18601231122
